Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

Phase 2 Terminated 37 enrolled National Institute of Allergy and Infectious Diseases (NIAID) ViiV Healthcare · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This study evaluated the potential drug-drug interactions between dolutegravir (DTG) and steady state rifapentine (RPT) when RPT was given with isoniazid (INH) daily for 4 weeks (1HP) as part of treatment for latent TB infection (LTBI) in HIV-1 and LTBI co-infected individuals.

Timeline

Start: 2021-02-27
Primary completion: 2021-12-15
Completion: 2021-12-27

Publications

Podany AT, Cramer Y, Imperial M, Rosenkranz SL, Avihingsanon A, Arduino R, Samaneka W, Gelmanova I, Savic R, Swindells S, Dawson R, Luetkemeyer AF. Twice-Daily Dolutegravir-Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis. 2024 Oct 15;79(4):983-989. doi: 10.1093/cid/ciae183.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dolutegravir	Other / unclassified	50 mg	Oral
Subject	Isoniazid	Small molecule	300 mg	Oral
Subject	Rifapentine	Small molecule	600 mg	Oral

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

Summary

Timeline

Publications

Drugs

Indications